Brain-derived neurotrophic factor as biomarker

To the Editor,

The publication on “Prognostic significance of brain-derived neurotrophic factor (BDNF) levels in patients with heart failure and reduced left ventricular ejection fraction” is very interesting (1). Barman et al. (1) concluded that decreased serum BDNF levels were associated with death and rehospitalization in patients with HF, suggesting their usefulness as prognostic biomarkers. As commented in the editorial, concurrent medical disorders can alter the clinical significance of BDNF (2). Nevertheless, there are other concerning factors regarding the usefulness of BDNF as a biomarker. For example, in laboratory medicine, poor reproducibility of the BDNF assay is common, which limits its usefulness as a biomarker (3). In addition, the conditions of blood sample collection and processing can significantly affect the BDNF levels (4). As reported by Tsuchimine et al. (5), anticoagulant compounds as well as the storage time and temperature during blood sampling can affect the measurements of plasma BDNF levels.

References

5. Tsuchimine S, Sugawara N, Ishioka M, Yasui-Furukori N. Preanaly-sis storage conditions influence the measurement of brain-derived neurotrophic factor levels in peripheral blood. Neuropsychobiology 2014; 69: 83-8. [CrossRef]

Address for Correspondence: Pathum Sookaromdee, MD, TWS Medical Center; Bangkok-Thailand
'Dr. DY Patil University; Pune-India

Author’s Reply

To the Editor,

We would like to thank the author(s) for their interest and valuable comments on our manuscript entitled “Prognostic significance of brain-derived neurotrophic factor (BDNF) levels in patients with heart failure and reduced left ventricular ejection fraction” (1). In the authors’ letter to the editor, the authors mentioned that there are potential concerns regarding the usefulness of BDNF as a biomarker.

The main aim of our study (1) was to investigate the relationship between BDNF levels in patients with heart failure (HF) and reduced left ventricular ejection fraction (LVEF), considering death or rehospitalization due to HF. Several recent studies have shown the association of BDNF with cardiovascular diseases. The prognostic significance of BDNF has been demonstrated in patients with hypertension, HF, and coronary artery disease (CAD) (2, 3). Because antidepressant medications can affect BDNF levels, patients with a history of a psychiatric disorder, such as major depressive disorder, schizophrenic disorder, or organic brain disorders, were excluded from our study. Like other studies that investigated the relationship between BDNF and heart failure (3-5), we measured BDNF levels using ELISA. Since BDNF is released from many tissues, such as brain, heart, endothelial, and skeletal muscle (6), it is unknown which organ decreases BDNF levels in patients with HF the most. It is believed that the mean serum BDNF levels are 100-fold higher than plasma levels because of platelet degranulation during the coagulation process (7). Because the majority of circulating BDNF is stored in platelets, it has been shown in the literature that the amount of BDNF in serum is similar to that in washed platelet lysates (8). Reliable biomarkers for diagnosis, treatment follow-up, and prognosis remain an unmet medical requirement. There is a consensus that BDNF can be an important measurable biomarker. However, future studies are needed to provide the basis for obtaining optimal BDNF measurements suitable for future clinical trials using human serum.

References

'Department of Cardiology, Okmeydani Training and Research Hospital; İstanbul-Turkey
2'Department of Cardiology, Bağcılar Training and Research Hospital; İstanbul-Turkey
3'Department of Cardiology, Istanbul Gaziosmanpaşa Taksim Training and Research Hospital; İstanbul-Turkey
4'Department of Cardiology, Cerrahpaşa Faculty of Medicine, İstanbul University; İstanbul-Turkey
5'Department of Cardiology, Faculty of Medicine, Koç University Hospital; İstanbul-Turkey